# Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

> **NCT03739866** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 53 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Lenacapavir
- **DRUG:** Placebo
- **DRUG:** B/F/TAF
- **DRUG:** TAF

## Key facts

- **NCT ID:** NCT03739866
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-26
- **Primary completion:** 2019-11-14
- **Final completion:** 2020-06-15
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2021-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03739866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03739866, "Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03739866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*